TGCT Support
  • Home
  • About TGCT
    • Causes of TGCT
    • Types of TGCT
    • Tumor Location
    • TGCT in Pediatrics
    • Diagnosis >
      • Biopsy
      • Imaging Features
  • Treatment
    • Surgery >
      • Recovery >
        • Surgery Guide
    • Medications >
      • Turalio >
        • Recommended Dosing
      • Romvimza
      • Imatinib
      • Common Side Effect of TGCT Drugs
    • Clinical Trials >
      • AMB-05X
      • Pimicotinib
      • Emactuzumab
      • Cabiralizumab
      • Lacnotuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Consensus Guideline
    • Our Research
    • Nutrition
    • Pain Management
    • Mental Health >
      • Find Mental Health Help
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
    • FAQs
  • News
    • Events
    • Patient Stories
  • About Us
    • Meet the Team
    • Medical Advisory Board
    • Partners >
      • TGCT Support France
    • Contact Us
    • Our Store
  • DONATE
    • GEM Program
  • Home
  • About TGCT
    • Causes of TGCT
    • Types of TGCT
    • Tumor Location
    • TGCT in Pediatrics
    • Diagnosis >
      • Biopsy
      • Imaging Features
  • Treatment
    • Surgery >
      • Recovery >
        • Surgery Guide
    • Medications >
      • Turalio >
        • Recommended Dosing
      • Romvimza
      • Imatinib
      • Common Side Effect of TGCT Drugs
    • Clinical Trials >
      • AMB-05X
      • Pimicotinib
      • Emactuzumab
      • Cabiralizumab
      • Lacnotuzumab
    • Radiation
  • Get Support
    • Join the Community >
      • Volunteer
      • Support Groups
    • TGCT Specialists
    • Consensus Guideline
    • Our Research
    • Nutrition
    • Pain Management
    • Mental Health >
      • Find Mental Health Help
    • Glossary of Terms
    • Educational Materials & Videos
    • Webinars
    • FAQs
  • News
    • Events
    • Patient Stories
  • About Us
    • Meet the Team
    • Medical Advisory Board
    • Partners >
      • TGCT Support France
    • Contact Us
    • Our Store
  • DONATE
    • GEM Program

Emactuzumab

Emactuzumab

Emactuzumab (SynOx Therapeutics) is the name of a monoclonal antibody currently in trial for TGCT. Monoclonal antibodies are engineered protein that bind to one substance, in this case CSF1 at the cell source. Once it binds, the CSF1 cannot interact with surrounding cells, reducing growth and symptoms of disease.

It is a Phase 3 randomized study, meaning the optimal dose is known and the effectiveness is being investigated. The Phase 3 trial is known as TANGENT. It has started recruiting, starting at MedStar in DC and Sarcoma Oncology Research Center in California. Clinical trial sites in Belgium (Brussels), Italy (Bologna, Pisa, and Sicily), Netherlands (LUMC), Spain (Barcelona and Zaragoza), Taiwan (Taipei), Sweden (Lund), Switzerland (Basel), France (Lyon and other sites), Montreal and Toronto (Canada), and the UK (London) are open. Check back for more information as more sites open!


Published data from the Phase 1 trial suggests it has an improved tolerability profile and remains effective at shrinking TGCT in 71% of patients with a robust response for up to 800 study days (1). The most common side effects include itching (70%), lack of energy (62%), facial swelling (49%), extremity swelling (44%), eyelid swelling (37%), headaches (30%), nausea (29%), rash (29%), fatigue (24%), among others. Rarer side effects such as lupus-like events have occurred. 

To learn more and check the trial status, go to the Clinical Trial page, the trial website, or consult your doctor.


Emactuzumab Trial Website
Emactuzumab Patient Support Group
This group is for patients and caretakers only.

TGCT SUPPORT IS A PROGRAM OF THE LIFE RAFT GROUP

Picture
155 US Highway 46, Suite 202                      Wayne, NJ 07470                      [email protected]